Citation only
via Europe PMC
Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.
Xie B, Zhang W, Zhang Y, Liu L, You J, Li Q.
Frontiers in aging neuroscience · 2026
Abstract
Blood-based biomarkers (BBMs) are increasingly being integrated into Alzheimer's disease (AD) clinical pathways by providing scalable tools to track amyloid, tau, neurodegeneration, and inflammation dimensions of the ATN-I framework. As biological characterization and biomarker-informed assessment are increasingly integrated into AD care, there is growing interest in clinically applicable blood-based approaches capable of reflecting AD-related biological changes across different disease stages. This review examines recent advances in BBMs through the ATN-I framework while emphasizing their clinical decision value, analytical feasibility, economic considerations, and implementation barriers across different healthcare settings. Building on these findings, we examine the evidence supporting clinical use, with a focus on appropriate use criteria, clinical validation, laboratory feasibility, and consistent interpretation methods. Furthermore, this review explores how integrating BBMs with traditional cerebrospinal fluid and neuroimaging tests may support symptom-driven clinical triage, probability refinement, and early evaluation in selected individuals, improving clinical workflow efficiency and accessibility. Finally, the article addresses remaining challenges related to clinical validation, platform accessibility, cost-effectiveness, and equitable deployment, highlighting how emerging biomarker strategies may contribute to more scalable AD assessment.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fnagi.2026.1852137
- Canonical
- link ↗
- Fetched
- 2026-10-12 MST
Cite this
APA
B, X., W, Z., Y, Z., L, L., J, Y., & Q., L. (2026). Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring. <em>Frontiers in aging neuroscience</em>. https://doi.org/10.3389/fnagi.2026.1852137
Vancouver
B X, W Z, Y Z, L L, J Y, Q. L. Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring. Frontiers in aging neuroscience. 2026. doi:10.3389/fnagi.2026.1852137.
BibTeX
@article{xie2026Transl,
title = {Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.},
author = {Xie B and Zhang W and Zhang Y and Liu L and You J and Li Q.},
journal = {Frontiers in aging neuroscience},
year = {2026},
doi = {10.3389/fnagi.2026.1852137},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Current Alzheimer Research 2019
Citation only
Biomarkers for Alzheimer’s Disease
Chinese Medical Journal 2017
Open access · CC-BY
Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease
PLoS Medicine 2018
Open access · CC-BY
Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study
Acta Neuropathologica Communications 2021
Open access · CC-BY
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease
Circulation 2026
Citation only
Abstract WE481: Disrupted Circadian Rest-Activity Rhythms and Incident Heart Failure in the Aging Population: The Atherosclerosis Risk in Communities Study
Maastricht University Medical Center 2022
Open access · US-GOV